Drugs / Mencevax ACW
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00994695 | Nov 2005 → Jan 2006 | meningococcal meningitis | Armauer Hansen Research Institute, Ethiopia | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00317109 | Apr 2006 → May 2007 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mencevax ACW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00994695 ↗ |
| Known as | Mencevax ACWY | “Mencevax™ ACWY was changed to Mencevax™ ACW throughout the posting to correct an inconsistency in the earlier version of the protocol posting and to reflect the actual situation.” NCT00317109 ↗ |
| Modality | Vaccine | “Mencevax™ Group A, C and W135 polysaccharide meningococcal vaccine (ACW)” NCT00317109 ↗ |
| Route | Subcutaneous | “One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months” NCT00317109 ↗ |